trial
as of 2026-07-01Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
NCTId NCT01964404
at a glance
Phase 1 · Completed
Enrollment 263 (actual)
Sponsored by Dartmouth-Hitchcock Medical Center
Primary completion 2021-09-18
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
263 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-07
Primary completion
2021-09-18
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Dartmouth-Hitchcock Medical CenterLead Sponsor
Columbia UniversityCollaborator
Harvard Medical School (HMS and HSDM)Collaborator
Massachusetts Institute of TechnologyCollaborator
Massachusetts General HospitalCollaborator
Nathan Kline Institute for Psychiatric ResearchCollaborator
University of VermontCollaborator
National Institute on Drug Abuse (NIDA)Collaborator
Investigators
1
Mary F. Brunette, MDPrincipal Investigator
Sites
2 total
Lebanon, United StatesBurlington, United States
Facts & assertions
4 sourced
Enrollment
263
Phase
PHASE1
Primary Completion Date
2021-09-18
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
collaborator
company
indication
investigator
person